CURRICULUM VITAE

MARCELLO MAGGIOLINI

Professore Ordinario di Patologia Generale (SSD: MED/04)

Dipartimento di Farmacia e Scienze della Salute e della Nutrizione

Università della Calabria

Formazione e attività accademica:

1981 Laurea in Medicina e Chirurgia - Università di Padova -110/110 e lode

1985 Specializzazione in Endocrinologia con il massimo dei voti,
Università Cattolica di Roma, Policlinico A. Gemelli

1989 Specializzazione in Genetica Medica con il massimo dei voti
Università di Catania

1993-1998 Professore a Contratto, Facoltà di Farmacia, Università della Calabria

1998-1999 Visiting Professor, Dip. Biologia Cellulare e Molecolare, Università di Ginevra

1999 Ricercatore, Facoltà di Farmacia, Università della Calabria

2001 Professore Associato, Facoltà di Farmacia, Università della Calabria

2005 Professore Ordinario, Facoltà di Farmacia, Università della Calabria

2005-2012 Direttore Dipartimento Farmaco-Biologico, Università della Calabria

2006-2012 Componente del Senato Accademico, Università della Calabria

2008-2012 Presidente del Consiglio dei Direttori di Dipartimento, Università della Calabria

1993-1997 Componente Consiglio di Amministrazione, Università della Calabria

2013-2019 Componente del Consiglio di Amministrazione, Università della Calabria

Dal 2021 Coordinatore Corso di Laurea in Medicina e Chirurgia-Tecnologie Digitali, Università della Calabria

2021-2023 Membro Commissione ASN - Settore Concorsuale 06 A2

Indici bibliometrici Scopus (febbraio 2023) : H-index: 57 ; citazioni: 10.900; n. pubblicazioni su riviste scientifiche internazionali: 194
(https://www.scopus.com/authid/detail.uri?authorId=6701310626)

Attività didattica:

1993-1994 Professore a Contratto (art.100 DPR 382/80) per l'insegnamento di Biologia Generale nel Corso di Laurea in Chimica e Tecnologia Farmaceutiche, Facoltà di Farmacia, Università della Calabria

1994-1999 Professore a Contratto (art.100 DPR 382/80) per l'insegnamento di Patologia Generale nel Corso di Laurea in Chimica e Tecnologia Farmaceutiche, Facoltà di Farmacia, Università della Calabria

2002-2003 Docente dell'insegnamento di Igiene dei Corsi di Laurea in Tecnologia dei Prodotti Cosmetici e Informazione Scientifica del Farmaco della Facoltà di Farmacia, Università della Calabria

2003-2004 Docente dell'insegnamento di Microbiologia (con elementi di educazione sanitaria) dei Corsi di Laurea in Tecnologia dei Prodotti Cosmetici e Informazione Scientifica del Farmaco, Facoltà di Farmacia, Università della Calabria

1994 ad oggi Docente della Scuola di Specializzazione in Patologia Clinica, Dipartimento di Farmacia, Università della Calabria

1999 ad oggi Titolare dell'insegnamento di Patologia Generale e Oncologia Sperimentale, Corso di Laurea in Chimica e Tecnologia Farmaceutiche, Dipartimento di Farmacia, Università della Calabria

2021 ad oggi Titolare dell'insegnamento di Patologia Generale, Corso di Laurea in Medicina e Chirurgia, Dipartimento di Farmacia, Università della Calabria

Coordinamento e partecipazione a progetti di ricerca:

2020: Responsabile Unità di Ricerca del progetto triennale: "Targeting novel insulin/IGF-driven signaling networks in breast cancer" approvato dal Ministero della Salute nell'ambito dei Progetti di Ricerca Finalizzata 2019 (codice progetto: RF-2019- 12368937).

2018: Coordinatore progetto di ricerca quinquennale finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Dissecting novel IGF system-activated transduction pathways toward combination therapeutic approaches in breast cancer".

2015: Coordinatore progetto di ricerca triennale finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Dissecting the role of G protein estrogen receptor (GPR30/GPER) in breast cancer".

2012 ad oggi: Coordinatore attività di ricerca laboratorio "OMICA" progetto S.I.L.A. (PONInfrastrutture 2007-2013).

2012: Coordinatore progetto di ricerca triennale finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Transduction mechanisms involved in the estrogenic GPER signaling in hormonesensitive tumors".

2012: Coordinatore progetto (PON Ricerca e Competitività 2007-2013): Identificazione di biomarcatori e sviluppo di metodi diagnostici e terapeutici nel campo dell'Oncologia e della Biologia vascolare".

2011: Coordinatore progetto di ricerca triennale finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Novel mechanisms of resistance to anti-hormone treatments in cancer patients and strategies of intervention".

2010: Coordinatore del progetto di ricerca finanziato dall'INAIL: "Il mesotelioma: meccanismi molecolari coinvolti e valutazione di parametri clinico-epidemiologici".

2009: Coordinatore progetto di ricerca triennale finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Functional role exerted by the novel membrane estrogen receptor GPR30 in hormone responsive tumors".

2008: Coordinatore nazionale del progetto PRIN "Interazioni funzionali tra recettori di membrana e nucleari nella trasduzione di segnali estrogenici e di fattori di crescita nei tumori ormono-responsivi".

2005: Coordinatore nazionale del progetto PRIN "Ruolo di recettori di membrana e nucleari nell'interazione funzionale tra segnali estrogenici e di fattori di crescita nei tumori ormonoresponsivi".

2005: Coordinatore progetto di ricerca triennale finanziato dall' Associazione Italiana Ricerca sul Cancro (AIRC): "Genetic and functional analysis of tumor markers of breast cancer cells".

2004: Coordinatore progetto di ricerca "Basi biomolecolari dell'attività esercitata dai fitoestrogeni nel tumore mammario" (Regione Calabria - L.R. 10/1998).

2003: Componente Unità di ricerca progetto PRIN: "Meccanismi molecolari attraverso cui JunD modula la proliferazione e la morte cellulare".

2003: Componente Unità di ricerca progetto finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Molecular mechanisms underlying the tumor suppressor activity of the multiple endocrine neoplasia I gene".

2001: Componente Unità di ricerca del progetto finanziato dall'Associazione Italiana Ricerca sul Cancro (AIRC): "Role of interaction between ERα and IRS-I signalling on cell adhesion and invasiveness in breast cancer".

2000: Componente Unità di ricerca del progetto PRIN: " trasduzione del segnale e regolazione di geni che controllano la proliferazione e la sopravvivenza cellulare".

1999: Componente Unità di ricerca del progetto CNR-UE: Eradicazione del gozzo endemico nell'Italia meridionale.

1996: Componente Unità di ricerca progetto POP-UE: "Basi biomolecolari dell'ormonodipendenza del tumore mammario umano ed effetti di nuove molecole antiestrogeniche sull'interazione funzionale tra recettori nucleari e recettori di membrana".

1993: Componente dell'Unità di ricerca progetto POP-UE: "Tipizzazione endocrina dei tumori ormono-dipendenti".

1993: Componente Unità di ricerca progetto "Concerted Action UE": "Calcium intake and peake bone mass intake del calcio in young female in 5 European Countries.

Editor/Board Member for the journals:
Journal of Translational Medicine
Cancer Communication
Molecular and Cellular Endocrinology
BioMedCentral Cancer
Frontiers Endocrinology (cancer section)
Scientific Reports
Cells
Cancers

Reviewer di progetti finanziati da :
MIUR, Ministero della Salute, Istituti ed Enti di ricerca pubblici e privati nazionali e internazionali.

PUBBLICAZIONI SU RIVISTE INTERNAZIONALI "PEER REVIEWED"

Insulin/IGF axis and the Receptor for Advanced Glycation End Products: role in meta-inflammation and potential in cancer therapy. Vella V, Lappano R, Bonavita E, Maggiolini M, Clarke RB, Belfiore A, De Francesco EM. Endocr Rev. 2023 Mar 4:bnad005.

Promising Perspectives of the Antiproliferative GPER Inverse Agonist ERα17p in Breast Cancer. Kampa M, Lappano R, Grande F, Rizzuti B, Maggiolini M, Castanas E, Jacquot Y. Cells. 2023 Feb 18;12(4):653.

Role of the G Protein-Coupled Receptors in Cancer and Stromal Cells: From Functions to Novel Therapeutic Perspectives. Lappano R, Maggiolini M. Cells. 2023 Feb 15;12(4):626.

Identification of a human estrogen receptor α tetrapeptidic fragment with dual antiproliferative and anti-nociceptive action. Jouffre B, Acramel A, Belnou M, Santolla MF, Talia M, Lappano R, Nemati F, Decaudin D, Khemtemourian L, Liu WQ, Maggiolini M, Eschalier A, Mallet C, Jacquot Y. Sci Rep. 2023 Jan 24;13(1):1326.

The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells. Santolla MF, Talia M, Cirillo F, Scordamaglia D, De Rosis S, Spinelli A, Miglietta AM, Nardo B, Filippelli G, De Francesco EM, Belfiore A, Lappano R, Maggiolini M. Cells. 2022 Aug 4;11(15):2402.

Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress.
De Francesco EM, Cirillo F, Vella V, Belfiore A, Maggiolini M, Lappano R.
Expert Opin Ther Targets. 2022 Jun;26(6):513-535.

G-Protein-Coupled Estrogen Receptor Expression in Rat Uterine Artery Is Increased by Pregnancy and Induces Dilation in a Ca2+ and ERK1/2 Dependent Manner.
Tropea T, Rigiracciolo D, Esposito M, Maggiolini M, Mandalà M.
Int J Mol Sci. 2022 May 26;23(11):5996.

Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, Zicarelli A, De Rosis S, Giordano F, Miglietta AM, De Francesco EM, Vella V, Belfiore A, Lappano R, Maggiolini M. J Transl Med. 2022 Jun 7;20(1):263.

Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Adame-Garcia SR, Arang N, Lubrano S, De Francesco EM, Belfiore A, Gutkind JS, Maggiolini M. J Exp Clin Cancer Res. 2022 Jun 3;41(1):193.

Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Lappano R, Todd LA, Stanic M, Cai Q, Maggiolini M, Marincola F, Pietrobon V. Cancers (Basel). 2022 Jan 21;14(3):539.

Assessment of androgen receptor, IGF-IR and insulin receptor expression in male patients with severe peripheral artery disease. Andreucci M, Rigiracciolo DC, Bracale UM, Ielapi N, Provenzano M, D'Iuorno D, Michael A, Mastroroberto P, Serraino GF, Maggiolini M, Serra R. Heliyon. 2022 Jan 12;8(1):e08756.

Translational signaling and systems biology. Maggiolini M.
J Transl Med. 2021 Nov 30;19(1):487.

Estrogen receptor variant ERα46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer-associated fibroblasts.
F. Cirillo, M. Pellegrino, M. Talia, I.D. Perrotta, D. C. Rigiracciolo, A. Spinelli, D. Scordamaglia, L. Muglia, R. Guzzi, A. M. Miglietta, E. M. De Francesco, A. Belfiore, M. Maggiolini, R. Lappano. Clin Transl Med. 2021 Nov;11(11):e516.

A Biocompatible Aspartic-Decorated Metal-Organic Framework with Tubular Motif Degradable under Physiological Conditions. Mon M, Bruno R, Lappano R, Maggiolini M, Di Donna L, Ferrando Soria J, Armentano D, Pardo E. Inorg Chem. 2021 Sep 20;60(18):14221-14229.

DDR1 Affects Metabolic Reprogramming in Breast Cancer Cells by Cross-Talking to the Insulin/IGF System. Vella V, Giuliano M, Nicolosi ML, Majorana MG, Marć MA, Muoio MG, Morrione A, Maggiolini M, Lappano R, De Francesco EM, Belfiore A. Biomolecules. 2021 Jun 22;11(7):926.

S100A4 Is Involved in Stimulatory Effects Elicited by the FGF2/FGFR1 Signaling Pathway in Triple-Negative Breast Cancer (TNBC) Cells. Santolla MF, Talia M, Maggiolini M. Int J Mol Sci. 2021 Apr 29;22(9):4720.

Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, Lappano R. Cancers (Basel). 2021 Feb 5;13(4):645.

Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer. Muoio MG, Talia M, Lappano R, Sims AH, Vella V, Cirillo F, Manzella L, Giuliano M, Maggiolini M, Belfiore A, De Francesco EM. Cancers (Basel). 2021 Feb 4;13(4):621.

Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling. Vella V, De Francesco EM, Lappano R, Muoio MG, Manzella L, Maggiolini M, Belfiore A. Front Cell Dev Biol. 2020 Dec 8;8:608412.

Newly Synthesized Imino-Derivatives Analogues of Resveratrol Exert Inhibitory Effects in Breast Tumor Cells. Iacopetta D, Lappano R, Mariconda A, Ceramella J, Sinicropi MS, Saturnino C, Talia M, Cirillo F, Martinelli F, Puoci F, Rosano C, Longo P, Maggiolini M. Int J Mol Sci. 2020 Oct 21;21(20):7797.

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives. Santolla MF, Maggiolini M. Cancers (Basel). 2020 Oct 18;12(10):3029.

Computational Approaches for the Discovery of GPER Targeting Compounds. Grande F, Occhiuzzi MA, Lappano R, Cirillo F, Guzzi R, Garofalo A, Jacquot Y, Maggiolini M, Rizzuti B. Front Endocrinol (Lausanne). 2020 Aug 4;11:517. doi: 10.3389/fendo.2020.00517. eCollection 2020.

The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Lappano R, Talia M, Cirillo F, Rigiracciolo DC, Scordamaglia D, Guzzi R, Miglietta AM, De Francesco EM, Belfiore A, Sims AH, Maggiolini M. J Exp Clin Cancer Res. 2020 Aug 10;39(1):153.

IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, Gutkind JS, Maggiolini M. Cells. 2020 Apr 18;9(4):1010.

Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Lappano R, Rigiracciolo DC, Belfiore A, Maggiolini M, De Francesco EM. Expert Opin Ther Targets. 2020 Jun;24(6):559-572.

The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis. Talia M, De Francesco EM, Rigiracciolo DC, Muoio MG, Muglia L, Belfiore A, Maggiolini M, Sims AH, Lappano R. Cells. 2020 Mar 4;9(3):622.

Interaction of the Anti-Proliferative GPER Inverse Agonist ERα17p with the Breast Cancer Cell Plasma Membrane: From Biophysics to Biology. Trichet M, Lappano R, Belnou M, Salazar Vazquez LS, Alves I, Ravault D, Sagan S, Khemtemourian L, Maggiolini M, Jacquot Y. Cells. 2020 Feb 15;9(2):447.

AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs). Cirillo F, Lappano R, Bruno L, Rizzuti B, Grande F, Guzzi R, Briguori S, Miglietta AM, Nakajima M, Di Martino MT, Maggiolini M. J Exp Clin Cancer Res. 2019 Aug 1;38(1):335.

The Peptide ERalpha 17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells. Lappano R, Mallet C, Rizzuti B, Grande F, Galli GR, Byrne C, Broutin I, Boudieu L, Eschalier A, Jacquot Y, Maggiolini M. Cells. 2019 Jun 14;8(6).

Differential MicroRNA Landscape Triggered by Estrogens in Cancer Associated Fibroblasts (CAFs) of Primary and Metastatic Breast Tumors. Vivacqua A, Muoio MG, Miglietta AM, Maggiolini M. Cancers (Basel). 2019 Mar 23;11(3).

GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression. Santolla MF, Vivacqua A, Lappano R, Rigiracciolo DC, Cirillo F, Galli GR, Talia M, Brunetti G, Miglietta AM, Belfiore A, Maggiolini M. Cells. 2019 Mar 7;8(3).

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. Cancer Cell. 2019. pii: S1535-6108(19)30043-1.

Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. Rigiracciolo DC, Santolla MF, Lappano R, Vivacqua A, Cirillo F, Galli GR, Talia M, Muglia L, Pellegrino M, Nohata N, Di Martino MT, Maggiolini M. J Exp Clin Cancer Res. 2019 Feb 6;38(1):58.

GPCR Modulation in Breast Cancer. Lappano R, Jacquot Y, Maggiolini M. Int J Mol Sci. 2018 Dec 2;19(12).

miR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer Associated Fibroblasts (CAFs). Vivacqua A, Sebastiani A, Miglietta AM, Rigiracciolo DC, Cirillo F, Galli GR, Talia M, Santolla MF, Lappano R, Giordano F, Panno ML, Maggiolini M. Cells. 2018 Nov 9;7(11)

Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT. De Francesco EM, Maggiolini M, Musti AM. Int J Mol Sci. 2018 Jul 10;19(7).

Functional characterization of the partially purified Sac1p independent adenine nucleotide transport system (ANTS) from yeast endoplasmic reticulum. Li Y, Cappello AR, Muto L, Martello E, Madeo M, Curcio R, Lunetti P, Raho S, Zaffino F, Frattaruolo L, Lappano R, Malivindi R, Maggiolini M, Aiello D, Piazzolla C, Capobianco L, Fiermonte G, Dolce V. J Biochem. 2018; 164(4):313322.

Notch1 Mediates Preconditioning Protection Induced by GPER in Normotensive and Hypertensive Female Rat Hearts. Rocca C, Femminò S, Aquila G, Granieri MC, De Francesco EM, Pasqua T, Rigiracciolo DC, Fortini F, Cerra MC, Maggiolini M, Pagliaro P, Rizzo P, Angelone T, Penna C. Front Physiol. 2018 May 15;9:521. doi: 10.3389/fphys.2018.00521. eCollection 2018.

The Physiopathological Role of the Exchangers Belonging to the SLC37 Family. Cappello AR, Curcio R, Lappano R, Maggiolini M, Dolce V. Front Chem. 2018 Apr 17;6:122. doi: 10.3389/fchem.2018.00122. eCollection 2018.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A. J Exp Clin Cancer Res. 2018 May 2;37(1):94.

GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer. Cirillo F, Pellegrino M, Malivindi R, Rago V, Avino S, Muto L, Dolce V, Vivacqua A, Rigiracciolo DC, De Marco P, Sebastiani A, Abonante S, Nakajima M, Lappano R, Maggiolini M. Oncotarget. 2017 Nov 20;8(63):106608-106624. doi: 10.18632/oncotarget.22541.

G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. De Francesco EM, Sotgia F, Clarke RB, Lisanti MP, Maggiolini M. Int J Mol Sci. 2017 Dec 14;18(12)

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment. De Francesco EM, Sims AH, Maggiolini M, Sotgia F, Lisanti MP, Clarke RB. Breast Cancer Res. 2017 Dec 6;19(1):129.

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). De Francesco EM, Bonuccelli G, Maggiolini M, Sotgia F, Lisanti MP. Oncotarget. 2017 Jun 9;8(40):67269-67286.

The lauric acid-activated signaling prompts apoptosis in cancer cells. Lappano R, Sebastiani A, Cirillo F, Rigiracciolo DC, Galli GR, Curcio R, Malaguarnera R, Belfiore A, Cappello AR, Maggiolini M. Cell Death Discov. 2017 Sep 18;3:17063.

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing antiangiogenic therapy. De Francesco EM, Maggiolini M, Tanowitz HB, Sotgia F, Lisanti MP. Oncotarget. 2017 Jun 12;8(34):56126-56142

Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer. Vivacqua A, De Marco P, Belfiore A, Maggiolini M. Curr Pharm Des. 2017;23(25):3658-3666.

A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. Pupo M, Bodmer A, Berto M, Maggiolini M, Dietrich PY, Picard D. Oncotarget. 2017 Jul 18;8(29):46728-46744

Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Lappano R, Maggiolini M. Drugs. 2017 Jun;77(9):951-965.

Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. Barton M, Filardo EJ, Lolait SJ, Thomas P, Maggiolini M, Prossnitz ER. J Steroid Biochem Mol Biol. 2017 Mar 25. doi: 10.1016/j.jsbmb.2017.03.021

GPER is involved in the functional liaison between breast tumor cells and cancer-associated fibroblasts (CAFs). Lappano R, Maggiolini M. J Steroid Biochem Mol Biol. 2017 Feb 27. doi: 10.1016/j. PMID: 28249728

Composition, Antifungal and Antiproliferative Activities of the Hydrodistilled Oils from Leaves and Flower Heads of Pterocephalus nestorianus Nab. Abdullah FO, Hussain FH, Mannucci B, Lappano R, Tosi S, Maggiolini M, Vidari G. Chem Biodivers. 2017 Feb 19. doi: 10.1002/cbdv.201700009.

Recent advances on the stimulatory effects of metals in breast cancer. Lappano R, Malaguarnera R, Belfiore A, Maggiolini M. Mol Cell Endocrinol. 2016; 457: 49-56

Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer. Vella V, Malaguarnera R, Lappano R, Maggiolini M, Belfiore A. Mol Cell Endocrinol. 2016; 457:57-72

Protective Role of GPER Agonist G-1 on Cardiotoxicity Induced by Doxorubicin. De Francesco EM, Rocca C, Scavello F, Amelio D, Pasqua T, Rigiracciolo DC, Scarpelli A, Avino S, Cirillo F, Amodio N, Cerra MC, Maggiolini M, Angelone T. J Cell Physiol. 2017;232(7):1640-1649.

Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Avino S, De Marco P, Cirillo F, Santolla MF, De Francesco EM, Perri MG, Rigiracciolo D, Dolce V, Belfiore A, Maggiolini M, Lappano R, Vivacqua A. Oncotarget. 2016;7:52710-52728

GPER, IGF-IR and EGFR transduction signalling are involved in stimulatory effects of zinc in breast cancer cells and cancer-associated fibroblasts. Pisano A, Santolla MF, De Francesco EM, De Marco P, Rigiracciolo DC, Perri MG, Vivacqua A, Abonante S, Cappello AR, Dolce V, Belfiore A, Maggiolini M, Lappano R. Mol Carcinog. 2017; 56(2):580-593

Estrogen receptors and chronic venous disease. Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P, Maggiolini M, De Franciscis S. J Vasc Surg. 2016;64(2):538.

GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1beta/IL1R1 response. De Marco P Lappano R, Francesco EM, Cirillo F, PupoM,Avino S, Vivacqua A, Abonante S, Picard D, Maggiolini M. Sci Rep. 2016;6:24354.

Response to "Comment on 'Effects of Atrazine on Estrogen Receptor and G Protein-Coupled Receptor 30-Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblasts'". Lappano R, Pupo M, Maggiolini M. Environ Health Perspect. 2016;124(4):A65.

Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling. Lappano R, Rigiracciolo D, De Marco P, Avino S, Cappello AR, Rosano C, Maggiolini M, De Francesco EM. AAPS J. 2016;18(2):305-10.

GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor derived endothelial cells. Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, Avino S, De Marco P, Bussolati B, Maggiolini M, De Francesco EM. Oncotarget. 2016;7(1):94-111.

Protective Role of GPER Agonist G-1 on Cardiotoxicity Induced by Doxorubicin. De Francesco EM, Rocca C, Scavello F, Amelio D, Pasqua T, Rigiracciolo DC, Scarpelli A, Avino S, Cirillo F, Amodio N, Cerra MC, Maggiolini M, Angelone T. J Cell Physiol. 2017;232(7):1640-1649

IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR 199a-5p through the PI3K/AKT pathway. Matà R, Palladino C, Nicolosi ML, Presti AR, Malaguarnera R, Ragusa M, Sciortino D, Morrione A, Maggiolini M, Vella V, Belfiore A. Oncotarget. 2016; 7(7): 7683-7700

Estrogen Signaling. R. Lappano and M. Maggiolini. Encyclopedia of Cancer, Springer-Verlag Berlin Heidelberg 2015.

The G Protein Estrogen Receptor (GPER) is Regulated by Endothelin-1 Mediated Signalling in Cancer Cells. Bartella V, De Francesco EM, Perri MG, Curcio R, Dolce V, Maggiolini M, Vivacqua A. Cell Signal. 2016;28(2):61-71.

GPER Mediates Non-Genomic Effects of Estrogen. Pupo M, Maggiolini M, Musti AM. Methods Mol Biol. 2016;1366:471-88.

Macromolecular Modelling and Docking Simulations for the Discovery of Selective GPER Ligands. Rosano C, Ponassi M, Santolla MF, Pisano A, Felli L, Vivacqua A, Maggiolini M, Lappano R. AAPS J. 2016;18(1):41-6.

Pregnancy Augments G Protein Estrogen Receptor (GPER) Induced Vasodilation in Rat Uterine Arteries via the Nitric Oxide - cGMP Signaling Pathway. Tropea T, De Francesco EM, Rigiracciolo D, Maggiolini M, Wareing M, Osol G, Mandalà M.PLoS One. 2015;10(11):e0141997.

SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Santolla MF, Avino S, Pellegrino M, De Francesco EM, De Marco P, Lappano R, Vivacqua A, Cirillo F, Rigiracciolo DC, Scarpelli A, Abonante S, Maggiolini M. Cell Death Dis. 2015;6:e1834.

Copper activates HIF-1α/GPER/VEGF signalling in cancer cells. Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, De Marco P, Cirillo F, Cappello AR, Dolce V, Belfiore A, Maggiolini M, De Francesco EM. Oncotarget. 2015; vol 6(33), p. 34158-77

A Bodipy as a luminescent probe for detection of the G protein estrogen receptor (GPER). Papalia T, Lappano R, Barattucci A, Pisano A, Bruno G, Santolla MF, Campagna S, De Marco P, Puntoriero F, De Francesco EM, Rosano C, Maggiolini M, Bonaccorsi P. Org Biomol Chem. 2015; vol.13, p.10437-41

A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models. Lappano R, Rosano C, Pisano A, Santolla MF, De Francesco EM, De Marco P, Dolce V, Ponassi M, Felli L, Cafeo G, Kohnke FH, Abonante S, Maggiolini M. Dis Model Mech. 2015 Jul 16. pii: dmm.021071.

Estrogenic GPER signaling regulates mir144 expression in cancer cells and cancer-associated fibroblasts (CAFs). Vivacqua A, De Marco P, Santolla MF, Cirillo F, Pellegrino M, Panno ML, Abonante S, Maggiolini M. Oncotarget. 2015 Jun 30;6(18):16573-87.
Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts. Maggiolini M, Santolla MF, Avino S, Aiello F, Rosano C, Garofalo A, Grande F. Future Med Chem. 2015, 4:437-48.

Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. De Marco P, Cirillo F, Vivacqua A, Malaguarnera R, Belfiore A, Maggiolini M. Front Endocrinol (Lausanne). 2015, 6:30.

(6-bromo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (carbhydraz) acts as a GPER agonist in breast cancer cells. Sinicropi MS, Lappano R, Caruso A, Santolla MF, Pisano A, Rosano C, Capasso A, Panno A, Lancelot JC, Rault S, Saturnino C, Maggiolini M. Curr Top Med Chem. 2015, 11:1035-42.

Effects of Atrazine on Estrogen Receptor α- and G Protein-Coupled Receptor 30-Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblasts. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M. Environ Health Perspect. 2015, 5:493-9.

Different 6-Aryl-Fulvenes exert anti-proliferative effects on Cancer Cells. Sirignano E, Pisano A, Caruso A, Saturnino C, Sinicropi MS, Lappano R, Botta A, Iacopetta D, Maggiolini M, Longo P. Anticancer Agents Med Chem. 2015, 4:468-74.

GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs). Pupo M, Pisano A, Abonante S, Maggiolini M, Musti AM. Int J Biochem Cell Biol. 2014,46:56-67.

GPER is regulated by insulin in cancer cells and cancer-associated fibroblasts (CAFs). De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, Pezzi V, Belfiore A, Maggiolini M. Endocr Relat Cancer. 2014;21(5):739-53.

Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Catalano S, Giordano C, Panza S, Chemi F, Bonofiglio D, Lanzino M, Rizza P, Romeo F, Fuqua SA, Maggiolini M, Andò S, Barone I. Breast Cancer Res Treat. 2014, 2:273-85.

GPER mediates activation of HIF-1α/VEGF signaling by estrogens. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, Maggiolini M. Cancer Res. 2014, 15:4053-64.

GPER Function in Breast Cancer: An Overview. Lappano R, Pisano A, Maggiolini M. Front Endocrinol (Lausanne). 2014;5:66.

Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Santolla MF, De Francesco EM, Lappano R, Rosano C, Abonante S, Maggiolini M. Cell Signal. 2014;26(7):1466-75.

Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M, Belfiore A. Endocrinology. 2014;155(4):1207-21

New titanocene derivatives with high antiproliferative activity against breast cancer cells. Saturnino C, Sirignano E, Botta A, Sinicropi MS, Caruso A, Pisano A, Lappano R, Maggiolini M, Longo P. Bioorg Med Chem Lett. 2014;24(1):136-40

Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Chimento A, Casaburi I, Rosano C, Avena P, De Luca A, Campana C, Martire E, Santolla MF, Maggiolini M, Pezzi V, Sirianni R. Mol Nutr Food Res. 2014;58(3):478-89.

Multisite phosphorylation of c-Jun at threonine 91/93/95 triggers the onset of c-Jun pro-apoptotic activity in cerebellar granule neurons. Reddy CE, Albanito L, De Marco P, Aiello D, Maggiolini M, Napoli A, Musti AM. Cell Death Dis. 2013;4:e852.

The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, Romeo F, Ferraro A, Lanzino M, Aquila S, Maggiolini M, Mauro L, Morelli C, Andò S. Cell Cycle. 2013;12(21):3405-20.

GPER mediates cardiotropic effects in spontaneously hypertensive rat hearts. De Francesco EM, Angelone T, Pasqua T, Pupo M, Cerra MC, Maggiolini M. PLoS One. 2013;8(8):e69322.

HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. Breast Cancer Res. 2013;15(4):R64.

The nuclear localization signal is required for nuclear GPER translocation and function in breast Cancer-Associated Fibroblasts (CAFs). Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S, Gasperi-Campani A, Pezzi V, Maggiolini M. Mol Cell Endocrinol. 2013;376(1-2):23-32.

Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives. Sirignano E, Saturnino C, Botta A, Sinicropi MS, Caruso A, Pisano A, Lappano R, Maggiolini M, Longo P. Bioorg Med Chem Lett. 2013;23(11):3458-62.

Cross-talk between GPER and growth factor signaling. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V, Maggiolini M. J Steroid Biochem Mol Biol. 2013;137:50-56

G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17-beta estradiol in cancer cells and cancer-associated fibroblasts. Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua A, Sisci D, Abonante S, Iacopetta D, Cappello AR, Dolce V, Maggiolini M. J Biol Chem. 2012;287(52):43234-45.

Recent advances in the rationale design of GPER ligands. Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolini M. Curr Med Chem. 2012;19(36):6199-206.

Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C, Maggiolini M. Environ Health Perspect. 2012;120(8):1177-82

New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. Cell Signal. 2012 (8):1515-21

Insulin-like growth factor-I regulates GPER expression and function in cancer cells. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, Pezzi V, Belfiore A, Maggiolini M. Oncogene. 2013;32(6):678-88.

Chimento A, Sirianni R, Casaburi I, Ruggiero C, Maggiolini M, Andò S, Pezzi V (2012). 17beta-estradiol activates GPER- and ESR1-dependent pathways inducing apoptosis in GC-2 cells, a mouse spermatocyte-derived cell line. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 355, p. 49-59

Pancotti F, Roncuzzi L, Maggiolini M, Gasperi-Campani A (2012). Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. CELLULAR SIGNALLING, vol. 24, p. 1390-1397

Lappano R, Maggiolini M (2012). GPCRs and cancer. ACTA PHARMACOLOGICA SINICA, vol. 33, p. 351-362

Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M (2012). GPER mediates the Egr-1 expression induced by 17beta -estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. BREAST CANCER RESEARCH AND TREATMENT, vol. 133, p. 1025-1035

Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, Maggiolini M (2012). MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells. BREAST CANCER RESEARCH, vol. 14, p. 1-13

Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, Ponassi M, Spallarossa A, Ranise A, Maggiolini M (2012). Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells. CURRENT CANCER DRUG TARGETS, vol. 12, p. 531-542

Filice E, Angelone T, De Francesco EM, Pellegrino D, Maggiolini M, Cerra MC (2011). Crucial Role of Phospholamban Phosphorylation and S-Nitrosylation in the Negative Lusitropism Induced by 17 beta-estradiol in the Male Rat Heart. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, vol. 28, p. 41-52

Lappano R, Maggiolini M (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. NATURE - DRUG DISCOVERY - vol. 10, p. 47-60

Dolce V, Cappello AR, Lappano R, Maggiolini M (2011). Glycerophospholipid synthesis as a novel drug target against cancer . CURRENT MOLECULAR PHARMACOLOGY, vol. 4, p. 167-175

Chimento A, Sirianni R, Zolea F, Bois C, Delalande C, Ando S, Maggiolini M, Aquila S, Carreau S, Pezzi V (2011). Gper and ESRs are expressed in rat round spermatids and mediate oestrogendependent rapid pathways modulating expression of cyclin B1 and Bax. INTERNATIONAL JOURNAL OF ANDROLOGY, vol. 34, p. 420-429

Rago V, Romeo F, Giordano F, Maggiolini M, Carpino A (2011). Identification of the estrogen receptor GPER in neoplastic and non-neoplastic human testes. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2011; 9: 135

Martinez-Lillo J, Mastropietro TF, Lappano R, Madeo A, Alberto ME, Russo N, Maggiolini M, De Munno G (2011). Rhenium (IV) compounds inducing apoptosis in cancer cells. CHEMICAL COMMUNICATIONS, vol. 47, p. 5283-5285

Rosano C, Stec-Martyna E, Lappano R, Maggiolini M (2011). Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators RID D-5386-2011. CURRENT MEDICINAL CHEMISTRY, vol. 18, p. 1188-1194

Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, Maggiolini M (2011). The Cholesterol Metabolite 25-Hydroxycholesterol Activates Estrogen Receptor alphaMediated Signaling in Cancer Cells and in Cardiomyocytes. PLOS ONE, vol. 6, p. 1-14

Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Ando S, Maggiolini M (2011). The G Protein-coupled Receptor 30 Is Up-regulated by Hypoxia-inducible Factor-1 alpha (HIF-1

alpha) in Breast Cancer Cells and Cardiomyocytes. THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, p. 10773-10782

Sisci D, Middea E, Morelli C, Lanzino M, Aquila S, Rizza P, Catalano S, Casaburi I, Maggiolini M, Ando S (2010). 17 beta-Estradiol enhances alpha(5) integrin subunit gene expression through ER alpha-Sp1 interaction and reduces cell motility and invasion of ER alpha-positive breast cancer cells. BREAST CANCER RESEARCH AND TREATMENT, vol. 124, p. 63-77

Chimento A, Sirianni R, Delalande C, Silandre D, Bois C, Andò S, Maggiolini M, Carreau S, Pezzi V (2010). 17 beta-estradiol activates rapid signaling pathways involved in rat pachytene spermatocytes apoptosis through GPR30 and ER alpha. . MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 320, p. 136-144

Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC. (2010). A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat . JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 60, p. 3-10

Mauro L, Pellegrino M, Lappano R, Vivacqua A, Giordano F, Palma MG, Andò S, Maggiolini M (2010). E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor. BREAST CANCER RESEARCH AND TREATMENT, vol. 121, p. 79-89

Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M (2010). Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 320, p. 162-170

Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M, Ando S (2010). Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. NUCLEIC ACIDS RESEARCH, vol. 38, p. 5351-5365

Madeo A, Maggiolini M (2010). Nuclear Alternate Estrogen Receptor GPR30 Mediates 17 betaEstradiol-Induced Gene Expression and Migration in Breast Cancer-Associated Fibroblasts. CANCER RESEARCH, vol. 70, p. 6036-6046

Sirianni R, Chimento A, De Luca A, Casaburi I, Rizza P, Onofrio A, Iacopetta D, Puoci F, Ando S, Maggiolini M, Pezzi V (2010). Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation. MOLECULAR NUTRITION & FOOD RESEARCH, vol. 54, p. 833-840

Iacopetta D, Lappano R, Cappello AR, Madeo M, De Francesco EM, Santoro A, Curcio R, Capobianco L, Pezzi V, Maggiolini M, Dolce V (2010). SLC37A1 Gene expression is up-regulated by epidermal growth factor in breast cancer cells. BREAST CANCER RESEARCH AND TREATMENT, vol. 122, p. 755-764

Maggiolini M, Picard D. (2010). The unfolding stories of GPR30, a new membrane-bound estrogen receptor. JOURNAL OF ENDOCRINOLOGY, vol. 204, p. 105-114

Madeo A, Vinciguerra M, Lappano R, Galgani M, Gasperi-Campani A, Maggiolini M, Musti AM. (2010). c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. ONCOGENE, vol. 29, p. 978-991

Recchia AG, Filice E, Pellegrino D, Dobrina A, Cerra MC, Maggiolini M (2009). Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. journal of molecular and cellular cardiology

Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D (2009). Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO journal, vol. 28, p. 523-532

Panno ML, Giordano F, Palma MG, Bartella V, Rago V, Maggiolini M, Sisci D, Lanzino M, De Amicis F, Ando S (2009). Evidence that Bergapten, Independently of its Photoactivation, Enhances p53 Gene Expression and Induces Apoptosis in Human Breast Cancer Cells. CURRENT CANCER DRUG TARGETS, vol. 9, p. 469-481

Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S, Maggiolini M (2009). G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. . MOLECULAR ENDOCRINOLOGY, vol. 23, p. 1815-1826

Sirianni R, Chimento A, De Luca A, Zolea F, Carpino A, Rago V, Maggiolini M, Andò S, Pezzi V (2009). Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. JOURNAL OF BIOLOGICAL CHEMISTRY, p. 28905-28916

Prossnitz ER, Maggiolini M (2009). Mechanisms of estrogen signaling and gene expression via GPR30. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 308, p. 32-38

Genua M, Pandini G, Sisci D, Castoria G, Maggiolini M, Vigneri R, Belfiore A (2009). Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. . CANCER RESEARCH, vol. 69, p. 7270-7277

Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Andò S, Pezzi V, Maggiolini M (2009). Structure-activity relationships of resveratrol and derivatives in breast cancer cells . MOLECULAR NUTRITION & FOOD RESEARCH, vol. 53, p. 845-858

M. Canonaco, G. Giusi, A. Madeo, R.M. Facciolo, R. Lappano, Maggiolini M (2008). A sexually dimorphic distribution pattern of the novel estrogen receptor GPR30 in some brain areas of the hamster. JOURNAL OF ENDOCRINOLOGY, vol. 196, p. 131-138

L. Albanito, D. Sisci, S. Aquila, E. Brunelli, A. Vivacqua, A. Madeo, R. Lappano, D.P. Pandey, D. Picard, L. Mauro, S. Andò, M. Maggiolini (2008). EGF induces GPR30 expression in estrogen receptor-negative breast cancer cells. ENDOCRINOLOGY, vol. 149, p. 3799-3808

M. Vinciguerra, I. Esposito, S. Salzano, A. Madeo, G. Nagel, M. Maggiolini, A. Gallo, A. M. Musti (2008). Negative charged threonine 95 of c-Jun is essential for c-Jun N-terminal kinase-dependent phosphorylation of threonine 91/93 and stress-induced c-Jun biological activity. THE

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 40, p. 307-316

R. Sirianni, A. Chimento, C. Ruggiero, A. De Luca, R. LAPPANO, S. ANDÒ, M. MAGGIOLINI, V. Pezzi (2008). The novel estrogen receptor GPR30 mediates the proliferative effects induced by 17beta- estradiol on mouse spermatogonial cells. ENDOCRINOLOGY, vol. 10, p. 5043-5051

L. Albanito, A. Madeo, R. Lappano, A. Vivacqua, V. Rago, A. Carpino, T. Oprea, E. Prossnitz, A. M. Musti, S. Ando', M. Maggiolini (2007). G protein-coupled receptor GPR30 mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. CANCER RESEARCH, vol. 67, p. 1859-1866

A. Vivacqua, D. Bonofiglio, L. Albanito, A. Madeo, V. Rago, A. Carpino, A. M. Musti, D. Picard, S. Ando, M. Maggiolini (2006). 17beta-estradiol, genistein and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. MOLECULAR PHARMACOLOGY, vol. 4, p. 1414-1423

Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, Qi H, Morelli C, Gentile M, Maggiolini M, Ando S (2006). Peroxisome Proliferator-Activated Receptor-{gamma} Activates p53 Gene Promoter Binding to the Nuclear Factor-{kappa}B Sequence in Human MCF7 Breast Cancer Cells. MOLECULAR ENDOCRINOLOGY, vol. 20, p. 3083-3092

A.Vivacqua, D. Bonofiglio, A. G. Recchia, A. M. Musti, D. Picard, S. Andò, M. Maggiolini (2006). The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17betaestradiol and hydroxytamoxifen in endometrial cancer cells. MOLECULAR ENDOCRINOLOGY, vol. 3, p. 631-646

Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De Rango F, Greco V, Maggiolini M, Feraco E, Mari V, Franceschi C, Passarino G, De Benedictis G. (2005). A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. GENOMICS, vol. 85, p. 258-263

D. Montanaro, Maggiolini M, A.G. Recchia, R. Sirianni, S. Aquila, L. Barzon, F. Fallo, S. Ando', V. Pezzi (2005). Antiestrogens upregulate ER beta expression and inhibit adrenocortical H295R cell proliferation. JOURNAL OF MOLECULAR ENDOCRINOLOGY,vol. 35, p.245-256

V. Gburcik, N. Bot, Maggiolini M, D. Picard (2005). SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. MOLECULAR AND CELLULAR BIOLOGY, vol. 25, p. 3421-3430

Maggiolini M, A.G. Recchia, D. Bonofiglio, S. Catalano, A. Vivacqua, A. Carpino, V. Rago, R. Rossi, S. Andò. (2005). The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 35, p. 269-281

Vinciguerra M, Vivacqua A, Fasanella I, Cuozzo C, Gallo A, Maggiolini M, Musti AM (2004). Differential Phosphorylation of c-Jun and JunD in Response to EGF is Determined by The Structure of MAPK Docking Sites. THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279 n.10, p. 9634-9641

V. Pezzi, R. Sirianni, A. Chimento, Maggiolini M, S. Bourguiba, C. Delalande, S. Carreau, S. Andò, E. Simpson, C. Clyne (2004). Differential expression of SF-1/AD4BP and LRH-1/FTFin the rat testis: LRH-1 as a potential regulator of testicular aromatase expression. ENDOCRINOLOGY, vol. 145, p. 2186-2196

Rago V, Maggiolini M, Vivacqua A, Palma A, Carpino A (2004). Differential expression of estrogen receptors (ERalpha/ERbeta) in testis of mature and immature pigs. ANATOMICAL RECORD. PART A, DISCOVERIES IN MOLECULAR, CELLULAR, AND EVOLUTIONARY BIOLOGY., vol. 281A(2), p. 1234-1239

Sisci D, Aquila S, Middea E, Gentile M, Maggiolini M, Mastroianni F, Montanaro D, Andò S. (2004). Fibronectin and type IV Collagen activate ERa AF-1 by c-Src pathway: Effect on breast cancer cell motility. ONCOGENE, vol. 23(55), p. 8920-8930

A. Carpino, B. Bilinska, L. Siciliano, Maggiolini M, V. Rago (2004). Immunolocalization of estrogen receptor beta in epididymis of mature and immature pigs. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, vol. 42, p. 13-17

S. Catalano, L. Mauro, S. Marsico, C. Giordano, P. Rizza, V. Rago, D. Montanaro, M. Maggiolini, M.L. Panno, S. Andò (2004). Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha (ERalpha) in MCF-7 cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279(19), p. 19908-19915

M. Maggiolini, A. Vivacqua, G. Fasanella, A.G. Recchia, D. Sisci, V. Pezzi, D. Montanaro, A.M. Musti, D. Picard, S. Andò (2004). The G protein-coupled receptor, GPR30, mediates via ERK1/ERK2 c-fos induction by 17beta-estradiol and phytoestrogens in breast cancer cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279(26), p. 27008-27016

M. Maggiolini, A.G. Recchia, A. Carpino, A. Vivacqua, G., Fasanella, V. Rago, V. Pezzi, P.A. Briand, D. Picard, S. Andò (2004). The estrogen receptor b is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 32, p. 777-791

Recchia A. G., Vivacqua A., Gabriele S., Carpino A., Fasanella G., Rago V., Bonofiglio D., Maggiolini M (2004). Xenoestrogens induce proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha. FOOD ADDITIVES AND CONTAMINANTS, vol. 21, p. 134-144

Vivacqua A., Recchia A. G., Fasanella G., Gabriele S., Carpino A., Rago V., Di Gioia M. L., Leggio A., Bonofiglio D., Liguori A., Maggiolini M (2003). The food contaminants bisphenol a and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. ENDOCRINE, vol. 22, p. 275-284

Maggiolini M, Bonofiglio D., Pezzi V., Carpino A., Marsico S., Rago V., Picard D., Andò S. (2002). Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 193, p. 13-18

Andò S., DE Amicis F., Rago V., Carpino A., Maggiolini M, Panno M.L., Lanzino M. (2002).

Breast cancer: from estrogen to androgen receptor Mol Cell Endocrinol. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 193, p. 121-127

Maggiolini M, Vivacqua A., Rago V., Loizzo M., Gabriele S., Menichini F., Andò S. (2002). Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 82, p. 315-322

Gallo A., Cuozzo C., Esposito I., Maggiolini M, Bonofiglio D., Vivacqua A., Garramone M., Weiss C., Bohmann D., Musti A.M. (2002). Menin uncouples ELK-1, JunD and c-Jun phosphorilation from MAP kinase activation. ONCOGENE, vol. 21, p. 6434-6445

Maggiolini M, Vivacqua A., Carpino A., Bonofiglio D., Fasanella G., Salerno M., Picard D., Andò S. (2002). The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. MOLECULAR PHARMACOLOGY, vol. 62, p. 1027-1035

Bonofiglio D, Maggiolini M, Catalano S, Marsico S, Aquila S, Andò S (2001). Bone mineral density is inversely related to parathyroid hormone in adolescent girls. HORMONE AND METABOLIC RESEARCH, vol. 3, p. 170-174

Maggiolini M, Bonofiglio D., Marsico S., Panno ML., Cenni B., Picard D., Ando' S. (2001). Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. MOLECULAR PHARMACOLOGY, vol. 60, p. 595-602

Bonofiglio D, Catalano S, Maggiolini M, Andò S (2001). Parathyroid hormone secretion in low calcium intake smokers. BRITISH JOURNAL OF NUTRITION, vol. 2, p. 307-312

Maggiolini M, Carpino A., Bonofiglio D., Pezzi V., Rago V., Marsico S, Picard D., Ando' S (2001). The direct proliferative stimulus of dehydroepiandrosterone on MCF7 breast cancer cells is potentiated by overexpression of aromatase. MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 184, p. 163-171

Kardinal AF, Hoorneman G, Vaananen K, Charles P, Andò S, Maggiolini M, Charzewska J, Rotily M, Deloraine A, Heikkinen J, Juvin R, Schaafsma G (2000). Determinants od bone mass and bone geometry in adolescent and young adult women. CALCIFIED TISSUE INTERNATIONAL, vol. 2, p. 81-89

Bonofiglio D, Maggiolini M, Catalano S, Marsico S, Aquila S, Giorno A, Andò S (2000). Parathyroid hormone is elevated but bone markers and density are normal in young female subjects who consume inadequate dietary calcium. BRITISH JOURNAL OF NUTRITION, vol. 1, p. 111-116

Maggiolini M, Donze' O., Picard D (1999). A non-radioactive method for inexpensive quantitative RT-PCR. BIOLOGICAL CHEMISTRY, vol. 380, p. 695-697

108.Maggiolini M, Donze' O., Jeannin E., Ando' S., Picard D (1999). Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. CANCER RESEARCH, vol. 59, p. 4864-4869

Van de Vijver LP, Kardinal AF, Charzewska J, Rotily M, Charles P, Maggiolini M, Andò S (1999). Calcium intake is weakly but consistently negatively associated with iron status in girls and women in six European countries. JOURNAL OF NUTRITION, p. 963-968

Bonofiglio D, Maggiolini M, Marsico S, Giorno A, Catalano S, Aquila S, Andò S (1999). Critical years and stages of puberty for radial bone mass apposition during adolescence. HORMONE AND METABOLIC RESEARCH, vol. 8, p. 478-482

Kardinal AF, Andò S, Charles P, Charzewska J, Rotily M, Vaananen K, Van Erp-Baart AM, Heikkinen J, Thomsen J, Maggiolini M, Deloraine A, Chabros E, Juvin R, Schaafsma G (1999). Dietary calcium and bone density in adolescent girls and young women in Europe. JOURNAL OF BONE AND MINERAL RESEARCH, vol. 4, p. 583-592

Maggiolini M, Bonofiglio D, Giorno A, Catalano S, Marsico S, Aquila S, Andò S (1999). The effects of dietary calcium intake on bone mineral density in healthy adolescent girls and young women inj southern italy. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, vol. 3, p. 479484

Sisci D, Panno ML, Salerno M, Maggiolini M, Pezzi V, Morrone EG, Mauro L, Aquila S, Marsico S, Lanzino M, Andò S (1997). A time course study on the in vitro effects of T3 and testosterone on androgen and estrogen receptors in peripuberal primary rat Sertoli cells. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, p. 218-224

Carpino A, De Sanctis V, Siciliano L, Maggiolini M, Vivacqua A, Pinamonti, A, Sisci D, Andò S (1997). Epididymal and sex accessory gland secretions in transfusion-dependent beta-thalassemic patients: evidence of an impaired prostatic function. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol. 3, p. 169-174

Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L, Morrone EG, Andò S (1996). Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF7 cells. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 12, p. 745-749

Panno ML, Salerno M, Lanzino M, De Luca G, Maggiolini M, Straface SV, Prati M, Palmero S, Bolla E, Fugassa E, Andò S (1995). Follo-up study on the effects of thyroid hormone administration on androgen metabolism of peripubertal rat Sertoli cells. EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 2, p. 236-241

Maggiolini M, De Luca G, Bria M, Sisci D, Aquila s, Pezzi V, Lanzino M, Giorno A, Tamburrini O, Della Sala M, Corcioni E, Brancati C, Andò S (1995). Follow-up study of thyroid function in polytransfused thalassemic patients. ENDOCRINE, vol. 2, p. 91-94

De Luca G, Maggiolini M, Bria M, Caracciolo M, Giorno A, Salerno M, Marsico S, Lanzino M, Brancati C, Andò S (1995). GH secretion in thalassemic patients with short stature. HORMONE RESEARCH, vol. 4, p. 158-163

Andò S, Maggiolini M, Di Carlo A, Diodato A, Bloise A, De Luca GP, Pezzi V, Sisci D, Mariano A, Macchia V (1994). Endemic goiter in calabria - etiopathogenesis and thyroid-function. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 17, p. 329-333

Ando S, Carpino A, Buffone M, Maggiolini M, Giacchetto C, Seidita F (1990). Fructose, prostatic acid-phosphatase and zinc levels in the seminal plasma of varicoceles. INTERNATIONAL JOURNAL OF FERTILITY, vol. 35, p. 249-252

Andò S, Carpino A, Buffone M, Maggiolini M, Sisci D (1989). The evaluation of free-l-carnitine, zinc and fructose in the seminal plasma of patients with varicocele and normozoospermia. ANDROLOGIA, vol. 21, p. 155-160

Andò S, Canonaco M, Valenti A, Aquila S, Tavolaro R, Maggiolini M, Panno ML, Dessì-Fulgheri F (1989). The invitro conversion of h-3 androstenedione to testosterone and dihydrotestosterone in the adrenal-gland of castrated male-rat influence of gonadal-steroid administration. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, vol. 93, p. 83-89

Canonaco M, Andò S, Valenti A, Tavolaro R, Panno ML, Maggiolini M, Dessì-Fulgheri F (1989). the invitro transformation of [h-3] dehydroepiandrosterone into its principal metabolites in the adrenal-cortex of adult castrated male-rats and following steroid treatment. JOURNAL OF ENDOCRINOLOGY, vol. 121, p. 419-424

Andò S, Canonaco M, Beraldi E, Valenti A, Maggiolini M, Piro A, Tavolaro R, Fulgheri FD (1988). The evaluation of androgen circulating levels following castration in adult male-rats. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, vol. 91, p. 311-318

Rende, 09/02/2023 Prof. Marcello Maggiolini